What’s the Buzz on Anti-VEGF Biosimilars?
Proponents of expanding the use of biosimilar anti-VEGFs point to their reduced production costs without compromising on quality or efficacy. As the U.S. patents for ranibizumab and aflibercept, two of the most common anti-VEGFs expire this year, a window of opportunity is opening.
…
latest posts